amyotrophic%20lateral%20sclerosis
AMYOTROPHIC LATERAL SCLEROSIS
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease with undetermined etiology that primarily involves the motor neurons in the cerebral cortex, brainstem and spinal cord.
There is no cure and the mean duration of survival is 2-5 years without tracheostomy and ventilator support.
Clinical hallmarks of ALS are: presence of upper & lower motor neuron features involving the brainstem and spinal cord and progressive limb weakness, respiratory insufficiency, spasticity, hyperreflexia, and bulbar symptoms such as dysarthria and dysphagia.

Amyotrophic%20lateral%20sclerosis Patient Education

Patient Education

Delivery of Diagnostic News

  • Ensure that diagnosis is given in person in a quiet, comfortable and private location
  • Patient’s family or caregiver should be present
  • Determine patient’s knowledge of amyotrophic lateral sclerosis (ALS)
    • Allow for questions and give reassurance
  • Respect cultural and social background of patient
  •  Provide written information about disease and support groups, if available
  •  Offer a second opinion, if the patient wants it

Reassurance

  • Explain complications are manageable
  • Involve patient in care decisions and reassure patient that their treatment decisions will be respected

Sharing of Information

  • Information needs to be provided to patient and family in a timely manner which is appropriate for decision making
    • Needs to be delivered well in advance of major management decisions (eg mechanical ventilation)

Genetic Counseling and Testing

  • Should be offered only in cases with known familial history of amyotrophic lateral sclerosis
  • Testing should be availed voluntarily and with informed consent
Editor's Recommendations
Most Read Articles
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Pearl Toh, 5 days ago
After treatment with fremanezumab, a difficult-to-treat patient population with treatment-resistant episodic or chronic migraine saw sustained benefits across a broad range of measures, according to multiple analyses of the FOCUS study released during the AHS 2020 Virtual Meeting.
Pearl Toh, 24 Jun 2020
While aducanumab significantly reduced clinical decline in individuals with early Alzheimer's disease (AD) in one randomized trial, no changes were seen in another identical study — rendering the role of aducanumab in AD inconclusive.
Roshini Claire Anthony, 13 Aug 2019

An active lifestyle, regardless of vascular risk, may delay the progression of Alzheimer’s disease (AD) by slowing down cognitive decline and neurodegeneration, according to a study presented at the Alzheimer’s Association International Conference (AAIC 2019).